Clearview rapid HIV test
This article was originally published in The Gray Sheet
Executive Summary
Clearview Complete HIV 1/2 is the latest rapid HIV test to gain a waiver for use in physicians' offices and clinics under the Clinical Laboratory Improvements Amendments, announced Nov. 2. The test, which uses "barrel" technology developed by StatSure Diagnostic Systems to detect antibodies in blood, serum and plasma, is manufactured by Chembio and marketed and distributed worldwide by Inverness Medical Innovations. Other CLIA-waived rapid HIV tests include OraSure's OraQuick Advance, Trinity's Uni-Gold Recombigen and Chembio's HIV 1/2 Stat-Pak (1"The Gray Sheet" Oct. 9, 2006, p. 16).
You may also be interested in...
Chembio Clears Path For HIV Tests With Patent, Marketing Agreement
Chembio settled its legal disputes and found a marketing partner for its recently approved rapid HIV tests in a three-party agreement announced Oct. 5
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.